Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms RO 7515629, RO7515629 |
Target |
Action stimulants, inhibitors |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), HLA-G inhibitors(major histocompatibility complex, class I, G inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Colorectal Cancer | Phase 1 | United States | 15 Jun 2023 | |
| MUC1 positive Solid Tumors | Phase 1 | United States | 15 Jun 2023 | |
| Non-Small Cell Lung Cancer | Phase 1 | United States | 15 Jun 2023 | |
| Ovarian Cancer | Phase 1 | United States | 15 Jun 2023 | |
| Pancreatic adenocarcinoma | Phase 1 | United States | 15 Jun 2023 | |
| Renal Cell Carcinoma | Phase 1 | United States | 15 Jun 2023 |






